# AI-Assisted ANVISA Submission Preparation

Last reviewed: October 15, 2026

Use structured extraction and expert review to prepare an ANVISA dossier from controlled source documentation, with missing evidence tracked explicitly.

Regulatory Overview

## AI-assisted ANVISA dossier preparation

Pure Global uses structured extraction, document mapping and professional review to support [ANVISA](https://www.pureglobal.com/glossary/anvisa) submission preparation. Automation can reduce repetitive assembly work, but its value depends on the source file's quality, language, device scope and remaining evidence gaps. It does not shorten an official review clock by itself or guarantee acceptance.

Start with [Brazil classification](https://www.pureglobal.com/markets/brazil/anvisa-medical-device-classification) and the applicable Notification or Registration route. A foreign FDA or CE dossier can provide useful evidence, but the Brazilian requirements and current approved configuration must be assessed independently.

## From source documents to a controlled filing

| Stage | Automation can support | Expert review must resolve |
| --- | --- | --- |
| Document inventory | Extract identifiers, revisions and product references | Which records are authoritative, current and within scope |
| Requirement mapping | Organize documents against the filing structure | Applicability, missing evidence and conflicting claims |
| Localization | Draft Portuguese field and text translations | Regulatory meaning, technical terms, labels and declarations |
| Assembly | Populate structured fields and cross-references | Correct device family, manufacturer/sites and route |
| Release | Generate a review package and issue list | Signed declarations, required certificates and final authorization |

Maintain traceability from each submitted statement to its source document and revision. Flag missing or conflicting information rather than generating a plausible replacement. Manufacturer declarations, original evidence and required third-party certificates cannot be invented by an automated workflow.

## Readiness checks before submission

Confirm the [Brazil holder](https://www.pureglobal.com/markets/brazil) and its permissions, intended use, model grouping, local class, [GMP evidence](https://www.gov.br/anvisa/pt-br/assuntos/produtosparasaude/mdsap/legislacao-de-produtos-para-a-saude), labeling and applicable [INMETRO/ANATEL requirements](https://www.pureglobal.com/markets/brazil/inmetro-anatel-medical-device-certification). Retain a controlled final package and a list of open issues. A notification route still requires compliant evidence even without a full premarket technical review.

The [ANVISA registration instructions](https://www.gov.br/anvisa/pt-br/setorregulado/regularizacao/produtos-para-saude/registro/registro-de-produtos) define the route, not the software used to assemble the file. Human approval should verify content, data accuracy and the actual legal requirements. Regulatory questions and changes after filing must be reflected in the controlled master.

## Scope, cost and lifecycle support

Define whether the engagement includes extraction, translation, gap assessment, dossier completion, local-holder services, filing, authority responses and maintenance. Government fees, certification/testing costs and additional evidence work should be identified separately. Use [Pure Global pricing](https://www.pureglobal.com/services/pricing) to discuss the current scope rather than assuming an annual fee covers every possible compliance activity.

Connect the final file to [Portuguese labeling](https://www.pureglobal.com/markets/brazil/anvisa-medical-device-labeling), [UDI/SIUD planning](https://www.gov.br/anvisa/pt-br/assuntos/produtosparasaude/udi) and [postmarket controls](https://www.pureglobal.com/markets/brazil/anvisa-medical-device-postmarket-surveillance). Faster preparation is useful only when the product and supporting evidence remain consistent and auditable.

How We Can Help

## Faster submissions. Predictable costs. Local support.

Plan your device registration, local representation and ongoing compliance with Pure Global.

[Contact us](https://www.pureglobal.com/contact)[Pricing](https://www.pureglobal.com/services/pricing?country=BR)

![Pure Global regulatory support team](https://www.pureglobal.com/assets/owned/dcb9486a9d--67ab304f89cb5422fdc63bc7__67ab304f89cb5422fdc63d7d_feature_1.webp)

## Frequently asked questions

### Does using AI guarantee faster ANVISA approval?

No. Automation can support preparation and document organization, but authority processing, technical questions, certification and evidence gaps remain separate. Any preparation estimate must be scoped to the actual file.

### Can AI fill missing test or clinical evidence?

No. Missing evidence must be identified and generated or otherwise justified through an acceptable method. The submission should retain traceability to real controlled documents, reviewed translations and authorized declarations.

### Does an annual service fee cover all government and certification costs?

The service proposal defines the professional scope. Government fees, laboratory work, third-party certification and additional evidence generation should be identified separately; consult the current pricing and written agreement.

## Single Process,  
Multiple Markets

When you partner with Pure Global, a single registration process opens doors to multiple countries. Our global subsidiaries make this streamlined path possible.

[

Argentina



](https://www.pureglobal.com/markets/argentina)

[

Australia



](https://www.pureglobal.com/markets/australia)

[

Bangladesh



](https://www.pureglobal.com/markets/bangladesh)

[

Brazil



](https://www.pureglobal.com/markets/brazil)

[

Canada



](https://www.pureglobal.com/markets/canada)

[

China



](https://www.pureglobal.com/markets/china)

[

Colombia



](https://www.pureglobal.com/markets/colombia)

[

Costa Rica



](https://www.pureglobal.com/markets/costa-rica)

[

Egypt



](https://www.pureglobal.com/markets/egypt)

[

European Union



](https://www.pureglobal.com/markets/european-union)

[

Hong Kong



](https://www.pureglobal.com/markets/hong-kong)

[

India



](https://www.pureglobal.com/markets/india)

[

Indonesia



](https://www.pureglobal.com/markets/indonesia)

[

Israel



](https://www.pureglobal.com/markets/israel)

[

Japan



](https://www.pureglobal.com/markets/japan)

[

Macau



](https://www.pureglobal.com/markets/macau)

[

Malaysia



](https://www.pureglobal.com/markets/malaysia)

[

Mexico



](https://www.pureglobal.com/markets/mexico)

[

New Zealand



](https://www.pureglobal.com/markets/new-zealand)

[

Pakistan



](https://www.pureglobal.com/markets/pakistan)

[

Peru



](https://www.pureglobal.com/markets/peru)

[

Philippines



](https://www.pureglobal.com/markets/philippines)

[

Saudi Arabia



](https://www.pureglobal.com/markets/saudi-arabia)

[

Singapore



](https://www.pureglobal.com/markets/singapore)

[

South Korea



](https://www.pureglobal.com/markets/south-korea)

[

Switzerland



](https://www.pureglobal.com/markets/switzerland)

[

Taiwan



](https://www.pureglobal.com/markets/taiwan)

[

Thailand



](https://www.pureglobal.com/markets/thailand)

[

UAE



](https://www.pureglobal.com/markets/uae)

[

United Kingdom



](https://www.pureglobal.com/markets/united-kingdom)

[

United States



](https://www.pureglobal.com/markets/united-states)

[

Vietnam



](https://www.pureglobal.com/markets/vietnam)

[Canonical page](https://www.pureglobal.com/markets/brazil/ai-brazil-anvisa-submissions)
